Denali Therapeutics Files 8-K
Ticker: DNLI · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1714899
| Field | Detail |
|---|---|
| Company | Denali Therapeutics Inc. (DNLI) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Denali Therapeutics filed a standard 8-K, no major news.
AI Summary
Denali Therapeutics Inc. filed an 8-K on January 13, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates Denali Therapeutics Inc. is meeting its regulatory reporting obligations, but it does not disclose any new material information that would immediately impact investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any specific new risks or material events.
Key Players & Entities
- Denali Therapeutics Inc. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 161 Oyster Point Blvd. (address) — Principal executive offices
- South San Francisco, California (location) — Principal executive offices location
FAQ
What is the primary purpose of this 8-K filing for Denali Therapeutics Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and Financial Statements and Exhibits.
On what date was this 8-K filing reported?
The 8-K filing was reported on January 13, 2025.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the state of incorporation for Denali Therapeutics Inc.?
Denali Therapeutics Inc. is incorporated in Delaware.
What is the principal executive office address for Denali Therapeutics Inc.?
The principal executive office address is 161 Oyster Point Blvd., South San Francisco, California 94080.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2025-01-13 08:03:25
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share DNLI NASDAQ Global Select Mar
Filing Documents
- dnli-20250113.htm (8-K) — 31KB
- ex991pressrelease1132025.htm (EX-99.1) — 31KB
- denali_txlogox02.jpg (GRAPHIC) — 664KB
- 0001714899-25-000054.txt ( ) — 1097KB
- dnli-20250113.xsd (EX-101.SCH) — 2KB
- dnli-20250113_lab.xml (EX-101.LAB) — 21KB
- dnli-20250113_pre.xml (EX-101.PRE) — 12KB
- dnli-20250113_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 13, 2025, Denali Therapeutics Inc. (the "Company") issued a press release announcing an update on its programs and expected milestones for 2025 and the Company's participation in the 43 rd Annual J.P. Morgan Healthcare Conference. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Item 7.01 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated January 13, 2025. 104 Cover Page Interactive Data File (formatted as Inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DENALI THERAPEUTICS INC. Date: January 13, 2024 By: /s/ Alexander O. Schuth Alexander O. Schuth, M.D. Chief Operating and Financial Officer